← Patent-cliff monitor small molecule NUZYRA OMADACYCLINE TOSYLATE
Loss of exclusivity October 2037 latest FDA-listed patent expiry
Drug detail Brand name NUZYRA Active ingredient OMADACYCLINE TOSYLATE Strength EQ 100MG BASE/VIAL Dosage form POWDER Route INTRAVENOUS Modality Small molecule FDA approval October 2018 Marketing status RX
Listed patents Patent Expires Type 10383884 October 2037 use U-2576 10835542 October 2037 use U-2576 10124014 March 2029 use U-2449 9724358 March 2029 use U-1569 9265740 March 2029 product
Regulatory exclusivity Code Expires M-320 May 2029 GAIN October 2028 NCE October 2023
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.